Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Mondelēz International to Participate in Barclays Global Consumer Staples Conference on September 3, 2025

CHICAGO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (Nasdaq: MDLZ) today announced that Dirk Van de Put, Chief Executive Officer and Luca Zaramella, Chief Financial Officer, w...

What impact might the disclosed information have on short‑term trading volumes and volatility of MDLZ stock? Could the conference reveal insights into regional performance, especially in emerging markets? Is there any update on the company’s progress toward its sustainability and ESG targets?
Symbol: MDLZ
Conference
25 days ago
Read more globenewswire

STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and...

What is the implied impact of the reported results on the company’s long‑term growth outlook and market share in dermatology? How does STRATA's gross margin and operating expense trends compare to its historical trends and industry averages? Are there any changes to the management team or board that could influence execution of the strategy?
Symbol: SSKN
Earnings
25 days ago
Read more globenewswire

Hyperfine, Inc. Reports Second Quarter 2025 Financial Results

GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powe...

Is there any insider buying or selling activity around the earnings announcement? Did management comment on macroeconomic factors, such as hospital budgeting or capital‑equipment spending trends, that could affect demand? What are the potential short‑term catalysts (e.g., earnings release, conference presentations) that could move the stock?
Symbol: HYPR
Earnings
25 days ago
Read more globenewswire

Highview Merger Corp. Announces Completion of $230,000,000 Initial Public Offering

Delray Beach, FL, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Highview Merger Corp. (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, including 3,000,000 unit...

How might the listing under two separate ticker symbols (HVMC and HVMCW) influence trading volume and price discovery for the securities? What is the projected market capitalization of HVMC once the warrants are exercised and the shares are fully diluted? How will the market react to the dual‑class structure (Class A shares and warrants) and what is the expected demand for each component?
Symbol: HVMC
Ipo
25 days ago
Read more globenewswire

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (A...

What macro‑economic or sector‑specific factors (e.g., biotech funding environment, FDA policy shifts) could amplify or mitigate the impact of this earnings release on the stock? How might the sentiment rating of 10 and the positive tone of the release translate into analyst upgrades or target price revisions? Is there any guidance on potential dilutive events (stock offerings, convertible debt) that could impact shareholder equity?
Symbol: ALLO
Earnings
25 days ago
Read more globenewswire

The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United Sta...

How might the reaffirmed full‑year guidance influence analyst sentiment and future earnings forecasts for TOI? Are there any risks or uncertainties highlighted in the release that could affect the company's guidance or stock performance? Did the company provide any updates on strategic initiatives, such as network expansion or new service lines, that could influence long‑term growth?
Symbol: TOI
Earnings
25 days ago
Read more globenewswire

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovat...

What is the potential impact of this earnings release on the stock's technical indicators and trading volume? How might the sentiment score of 10 influence market perception and short‑term price movement? Did the business update mention any changes in the capital structure, such as share issuances or debt financing, that could dilute existing shareholders?
Symbol: CYCC
Earnings
25 days ago
Read more globenewswire

Coherent Corp. Reports Fourth Quarter and Full Year Fiscal 2025 Results

SAXONBURG, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR) (“Coherent,” “We,” or the “Company”), a global leader in photonics, announced financial results today for the fiscal ...

What is the expected impact of the Q4 and full‑year results on Coherent Corp.'s stock price and valuation multiples relative to peers? Did any macro‑economic factors (e.g., supply‑chain constraints, demand cycles, or currency fluctuations) materially impact the results? How does the company's cash balance and liquidity compare to its debt obligations and upcoming financing needs?
Symbol: COHR
Earnings
25 days ago
Read more globenewswire

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fati...

What is the anticipated pricing and reimbursement strategy for Beziterim if approved? How does this trial compare to competitor pipelines targeting Long COVID or related post‑acute infection syndromes? What are the key risks if the trial fails to meet its endpoints?
Symbol: BIVV
Clinical trials
25 days ago
Read more globenewswire